不同剂量的干扰素-β对多发性硬化(MS)的疗效探讨

Observe the Curative Effect of Different Doses of Interferon-β on Multiple Sclerosis

目的探讨不同剂量的干扰素-β(IFN-β)治疗多发性硬化(MS)的效果。方法整群选取2012年3月—2014年3月入医院治疗的复发缓解型多发性硬化(RRMS)患者76例作为研究对象,根据用药剂量将患者分为大剂量组和小剂量组,大剂量组(38例)予以干扰素-β-1b(IFN-β1b)250μg行皮下注射,2 d用药1次;小剂量组(38例)予以IFN-β1b50μg行肌肉注射,2 d用药1次;行扩展残疾状况评分(EDSS),记录两组不良用药反应,随访6个月记录两组复发率、持续进展发生率。结果大剂量组局部注射部位疼痛、局部瘙痒的发生几率为39.47%、34.21%明显高于小剂量组15.79%、10.53%,差异具有统计学意义(P<0.05),不良反应在可耐受范围内;治疗48周大剂量组复发率和持续进展率分别为36.84%、18.42%均显著低于小剂量组,差异具有统计学意义(P<0.05)。结论大剂量IFN-β1b能够降低RRMS患者的疾病复发率和持续进展率,不良反应相对较多,但均在可耐受范围内。

Objective To investigate the effect of different doses of interferon beta(IFN- beta) in the treatment of multiple sclerosis(MS). Methods 76 patients were selected which were treated for relapse remitting multiple sclerosis(RRMS) in our hospital during March 2012 to March 2014 as the research object. According to the dosage, the patients were divided into large dose group and small dose group, large dose group with 38 cases received interferon-β-1b(IFN-β1b)250μg for subcutaneous injection once every two days, while small dose group with 38 cases received IFN-β1b 50μg for intramuscular injection once every 2 days. The expanded disability status score(EDSS) recorded two groups of adverse drug reaction, and followed up for 6 months to record the recurrence rate and the incidence rate of sustained progress. Results The large dose incidence rate of local injection site pain and local itching was 39.47% and 34.21% which was significantly higher than small dose group which were 15.79% and 10.53%. The difference was statistically significant(P<0.05). Adverse reactions were in the tolerance range. During the 48 weeks of treatment,the recurrence rate and the incidence rate of sustained progress of large dose group respectively were 36.84% and 18.42% which were significantly lower than small dose group. The difference was significant(P<0.05). Conclusion Large dose of IFN-β1b can reduce the recurrence rate and the incidence rate of sustained progress of patients with RRMS. Though adverse reactions are relatively high, but are in the range of tolerance